The differences in treating older versus younger CLL patients
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Commercialising leukemia and lymphoma therapies - future challenges
An introduction to the HOVON-141 trial in patients with CLL